U.S., July 3 -- ClinicalTrials.gov registry received information related to the study (NCT07046923) titled 'A Study of LY4175408 in Participants With Advanced Cancer' on June 24.
Brief Summary: The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Participation could last up to 4 years.
Study Start Date: July, 2025
Study Type: INTERVENTIONAL
Condition:
Carcinoma, Non-Small-Cell Lung
Small Cell Lung Carcinoma
Endometrial Neoplasms
Neoplasm Metastasis
Triple Negative Breast Cancer
Intervention:
DRUG: LY4175408
IV...